

## Appendix 4E – Preliminary Final Report

(ASX Listing rule 4.3A)

Company Name:	iSonea Limited (the 'Company')
ABN:	98 009 234 173
Reporting Period:	Financial year ended 30 June 2015
Previous Reporting Period:	Financial year ended 30 June 2014

### Results for Announcement to the Market

The results of iSonea Limited for the year ended 30 June 2015 are as follows:

Revenue	Down	53.11%	to	\$126,509
Loss after tax attributable to members	Down	47.00%	to	(\$5,464,443)
Net loss for the period attributable to members	Down	47.00%	to	(\$5,464,443)

#### Brief explanation of figures reported above

The loss for the Company after income tax for the reporting period was \$5,464,443 (2014: \$10,309,957) and before income tax the loss for the reporting period was \$5,464,443 (2014: \$10,309,957).

There is no tax payable or refund due during the current reporting period, (2014 payable or refund: \$0). This result has been achieved after fully expensing all research and development costs, in the current reporting period of \$3,054,345 (2014: \$3,841,215).

For further details relating to the current period's results, refer to the Operations Report contained within this document.

#### Dividends

No dividends have been paid or declared by the Company since the beginning of the current reporting period. No dividends were paid for the previous reporting period.

#### Net Tangible Assets

	30 June 2015	30 June 2014
Net Tangible Assets	\$3,351,908	\$8,426,447
Shares (No.)	281,588,816	275,913,955
Net Tangible Assets (Cents)	1.19	3.05

#### Loss per Share

	30 June 2015	30 June 2014
Basic loss per share (cents)	(1.94)	(3.91)
Diluted loss per share (cents)	(1.94)	(3.91)

#### Status of Audit of Accounts

These accounts are currently in the process of being audited. An Annual Report for the year ended 30 June 2015 containing the Audit Report shall be provided in due course.



ABN 98 009 234 173



# **Appendix 4E**

# **Preliminary Final Report**

For the Year Ended 30 June 2015

In Compliance with ASX Listing Rule 4.3A

# Table of Contents

---

**Review of Operations..... 4**

**Financial Report**

    Statement of Profit or Loss and Other Comprehensive Income .....6

    Statement of Financial Position.....7

    Statement of Changes in Equity .....8

    Statement of Cash Flows .....9

    Notes to the Financial Statements .....10

**Corporate Directory ..... 15**

# Review of Operations

---

The Directors of iSonea Limited (“ISN”, “iSonea” or “the Company”) provide the following Report in relation to the Company for the year ended 30 June 2015.

## Principal Activities

---

The Company's principal activities in the course of the financial year were the research, development and commercialisation of medical devices, and the production of Mobile Health applications. There were no significant changes in the nature of the Company's principal activities during the financial year.

The consolidated loss of the Company after providing for income tax amounted to \$5,464,443 (2014: \$10,309,957).

## Operations Report

---

The company made significant progress in fiscal 2015 to build shareholder value. Global and country partnerships either as joint ventures or sales and distribution agreements remain as our core monetisation objective.

However, prior to negotiating sound partnership relationships that would deliver value to shareholders, iSonea needed to build a much stronger and scalable technology platform and undertake fundamental changes to our core business operations. These were delivered.

### A Second Generation AirSonea® Wheeze Monitor

Testing of our first generation device revealed that incorrect positioning of the first Generation AirSonea® sensor could result in recordings without breath sounds and therefore no capacity to detect continuous adventitious breath sounds (CABS). In addition, new micro processing upgrades needed to be addressed.

Our Second Generation AirSonea® wheeze detection algorithm includes a breath-screening module to ensure the device will only record and pass sounds through to wheeze analysis when breath is detected. The app warns when breath is not detected and allows the user to reposition the sensor correctly without the need to stop the recording and start again.

Importantly, a totally new software IT infrastructure was built to support the AirSonea® device and App. The architecture supporting the original app was not stable or robust enough to support large numbers of consumers or regular updates, which would have resulted in the app crashing. Our new software from Two Bulls is more robust, scalable and secure. Further, it provides a substantially faster analysis of breath recordings and an app with a more engaging user interface.

The AirSonea® Asthma Wheeze Monitor and Asthma Management App is now ready for trials, recognising that app updates are, of course, a continuing process.

### AirSonea® Clinical trials in place

A trial of this second generation product will be conducted at a leading American university in order to help expedite its FDA clearance. The principal investigator is a renowned respiratory physician and the clinical team at the university reported that the device and app worked well in demonstration with the clinical team.

We expect the recruitment of patients will start towards the end of September and the trial should be completed by the end of December 2015. Full details will be advised after the trial receives protocol approval from the Institutional Review Board (Independent Ethics Committee). As previously advised, our current clinical trial has the objective of verifying that the Second Generation AirSonea® Wheeze Monitor is at least as accurate in detecting and quantifying wheeze as a consensus of a panel of physicians and trained experts.

### A Multi-Product Portfolio has been reintroduced that lowers risks for investors.

The Company has a strong portfolio of computerised wheeze detection products including AirSonea®, WHolter™, SonoSentry™, WheezoMeter™, PulmoTrack™ and the AsthmaSense™ App. All have been approved by the Australian TGA and carry the European Union's CE mark.

### **Business Turnaround**

Overall, the business structure has been dramatically simplified, costs substantially reduced and streamlined for clearer focus and accountability with more robust financial controls. Management is now based in Melbourne, Australia and Haifa, Israel. Senior Management previously resided in multiple locations including Maryland, Boston, San Diego and New York.

Management has specifically:

- Reduced cash burn from over \$900,000 per month to a forecast underlying burn rate of around \$240,000 per month.
- Consolidated the Company's Intellectual Property Portfolio with one service provider to ensure our patent strategy is implemented and that our IP is secured in relevant jurisdictions.
- Development of clinical trial protocols and a trial ready product for AirSonea® has been greatly assisted by the advice of global and local scientific consultants.
- Improved relationships with leading clinicians, healthcare professionals and peak Asthma bodies in Australia and overseas have been established.

### **Commercial Partnerships**

A broader focus on the whole portfolio of products has opened up substantially more commercial opportunities in both the home/ambulatory market and in hospital and clinical settings.

Thus iSonea already has an attractive portfolio to complement other product offerings in the health sector. Confidential discussions will continue during the current financial year.

### **Summary**

The company has built a strong management and technical team and excellent global medical and scientific relationships to be able to deliver the outcomes expected by shareholders when the new board was appointed prior to fiscal 2015.

# Statement of Profit or Loss and Other Comprehensive Income

## For the Year Ended 30 June 2015

	Note	Consolidated 30 June 2015 \$ AUD	Consolidated 30 June 2014 \$ AUD
<b>Revenue</b>			
Operating Revenue	3	93,988	18,975
Non-operating Revenue	3	32,521	250,843
<b>Total Revenue</b>		<b>126,509</b>	<b>269,818</b>
<b>Expenses</b>			
Amortisation expenses		(183,653)	(217,335)
Consulting, employee and director expenses		(1,399,296)	(1,997,072)
Equity-based payment expenses		(121,400)	(910,578)
Corporate administration expenses		(550,458)	(2,022,781)
Depreciation expenses		(32,550)	(27,269)
Marketing and promotion expenses		(27,400)	(1,760,301)
Fair value adjustment		-	661,812
Research and development expenses		(3,054,345)	(3,841,215)
Travel expenses		(221,850)	(465,036)
<b>Loss before income tax expense from continuing operations</b>		<b>(5,464,443)</b>	<b>(10,309,957)</b>
Income tax expense		-	-
<b>Loss after income tax for the year</b>		<b>(5,464,443)</b>	<b>(10,309,957)</b>
<b>Other comprehensive income:</b>			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Exchange differences on translation of foreign operations		167,035	42,609
<b>Total comprehensive income for the year</b>		<b>(5,297,408)</b>	<b>(10,267,348)</b>
Loss attributable to members of the parent entity		(5,464,443)	(10,309,957)
Total comprehensive income attributable to members of the parent entity		(5,297,408)	(10,267,348)
Loss per share for the year attributable to the members of the parent entity			
Basic loss per share (cents per share)	8	(1.94)	(3.91)
Diluted loss per share (cents per share)	8	(1.94)	(3.91)

The accompanying notes form part of these financial statements.

# Statement of Financial Position

As at 30 June 2015

	Note	Consolidated 30 June 2015 \$ AUD	Consolidated 30 June 2014 \$ AUD
<b>ASSETS</b>			
<b>Current Assets</b>			
Cash and cash equivalents		3,008,627	8,212,003
Trade and other receivables		69,861	84,211
Inventories		777,500	1,064,477
Other		702,824	494,170
<b>Total Current Assets</b>		<b>4,558,812</b>	<b>9,854,861</b>
<b>Non-Current Assets</b>			
Property, plant and equipment		74,811	96,771
Intangible assets		548,489	649,958
Other assets		2,848	2,619
<b>Total Non-Current Assets</b>		<b>626,148</b>	<b>749,348</b>
<b>TOTAL ASSETS</b>		<b>5,184,960</b>	<b>10,604,209</b>
<b>LIABILITIES</b>			
<b>Current Liabilities</b>			
Trade and other payables		1,265,366	1,508,305
Other financial liabilities		19,197	19,499
<b>Total Current Liabilities</b>		<b>1,284,563</b>	<b>1,527,804</b>
<b>TOTAL LIABILITIES</b>		<b>1,284,563</b>	<b>1,527,804</b>
<b>NET ASSETS</b>		<b>3,900,397</b>	<b>9,076,405</b>
<b>EQUITY</b>			
Issued capital	6	95,149,981	95,149,981
Reserves		177,821	426,737
Accumulated Losses		(91,427,405)	(86,500,313)
<b>TOTAL EQUITY</b>		<b>3,900,397</b>	<b>9,076,405</b>

The accompanying notes form part of these financial statements.

# Statement of Changes in Equity

## For the Year Ended 30 June 2015

	Issued Capital	Option Reserve	Foreign Currency Translation Reserve	Accumulated Losses	Total
CONSOLIDATED	\$ AUD	\$ AUD	\$ AUD	\$ AUD	\$ AUD
<b>Balance as at 30 June 2013</b>	<b>77,310,846</b>	<b>1,706,441</b>	<b>(477,129)</b>	<b>(76,917,741)</b>	<b>1,622,417</b>
Loss after income tax expense for the year	-	-	-	(10,309,957)	(10,309,957)
Other comprehensive income for the year, net of tax	-	-	42,609	-	42,609
<b>Total Comprehensive Income for the year</b>	<b>-</b>	<b>-</b>	<b>42,609</b>	<b>(10,309,957)</b>	<b>(10,267,348)</b>
<i>Transactions with Equity holders in their capacity as equity holders:</i>					
Shares Issued	17,398,376	-	-	-	17,398,376
Shares to be Issued	794,481	-	-	-	794,481
Capital Raising Costs	(1,093,722)	-	-	-	(1,093,722)
Options Exercised into Shares	-	(682,500)	-	-	(682,500)
Options Issued	-	1,304,701	-	-	1,304,701
Options Lapsed	740,000	(740,000)	-	-	-
Transfers to/from reserves <sup>1</sup>	-	(727,385)	-	727,385	-
<b>Balance at 30 June 2014</b>	<b>95,149,981</b>	<b>861,257</b>	<b>(434,520)</b>	<b>(86,500,313)</b>	<b>9,076,405</b>
Loss after income tax expense for the year	-	-	-	(5,464,443)	(5,464,443)
Other comprehensive income for the year, net of tax	-	-	167,035	-	167,035
<b>Total Comprehensive Income for the year</b>	<b>-</b>	<b>-</b>	<b>167,035</b>	<b>(5,464,443)</b>	<b>(5,297,408)</b>
<i>Transactions with Equity holders in their capacity as equity holders:</i>					
Options Issued	-	121,400	-	-	121,400
Transfers to/from reserves <sup>1</sup>	-	(537,351)	-	537,351	-
<b>Balance at 30 June 2015</b>	<b>95,149,981</b>	<b>445,306</b>	<b>(267,485)</b>	<b>(91,427,405)</b>	<b>3,900,397</b>

1. To transfer the value of lapsed/expired options from the reserve to accumulated losses.

The accompanying notes form part of these financial statements.



# Statement of Cash Flows

## For the Year Ended 30 June 2015

	Note	Consolidated 30 June 2015 \$ AUD	Consolidated 30 June 2014 \$ AUD
<b><u>Cash flows from operating activities</u></b>			
Receipts from customers		-	18,976
Payments to suppliers and employees (inclusive of GST)		(6,017,949)	(9,759,274)
Interest received		32,521	251,271
Receipt of R&D Tax Refund		-	390,787
Receipt of Grants		93,488	-
<b>Net cash flows used in operating activities</b>		<b>(5,891,940)</b>	<b>(9,098,240)</b>
<b><u>Cash flows related to investing activities</u></b>			
Proceeds from sales of plant and equipment		2,390	-
Payments for purchases of plant and equipment		(17,349)	(71,467)
Loans to unrelated entities		-	(32,813)
<b>Net cash flows used in investing activities</b>		<b>(14,959)</b>	<b>(104,280)</b>
<b><u>Cash flows related to financing activities</u></b>			
Proceeds from issues of securities		29,703	16,941,793
Capital raising costs		-	(853,600)
Other		(568)	(169)
<b>Net cash flows from financing activities</b>		<b>29,135</b>	<b>16,088,024</b>
<b>Net (decrease)/increase in cash and cash equivalents</b>		<b>(5,877,764)</b>	<b>6,885,504</b>
Cash and cash equivalents at the beginning of the year		8,212,003	1,346,736
Effects of exchange rate changes on cash and cash equivalents		674,388	(20,237)
<b>Cash and cash equivalents at the end of the year</b>		<b>3,008,627</b>	<b>8,212,003</b>

The accompanying notes form part of these financial statements.

# Notes to the Financial Statements

## Note 1 - Statement of Significant Accounting Policies

### Corporate Information

This Preliminary Financial Report covers the consolidated entity of iSonea Ltd and its controlled entities. The Company's principal activities are research, development and commercialisation of medical devices.

The Company's Preliminary Financial Report does not include all the notes of the type normally included in an Annual Financial Report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the entity as the full financial report.

This Preliminary Financial Report has been prepared in accordance with the recognition and measurement requirements, but not all disclosure requirements, of Australian Accounting Standards and Interpretations and the Corporations Act 2001. Australian Accounting Standards include Australian equivalents to International Financial Reporting Standards.

Significant accounting policies adopted in preparation of the preliminary financial report are consistent with those adopted by the company in preparation of the 30 June 2014 financial report and the 31 December 2014 half year financial report.

The Preliminary Final Report has been prepared on an accruals basis and is based on historical costs, except for the revaluation of certain non-current assets and financial instruments. Cost is based on fair values of the consideration given in exchange for assets.

The preliminary financial report is presented in Australian dollars.

## Note 2 - Dividends

The Company has resolved not to declare any dividends for the financial year ended 30 June 2015.

## Note 3 - Revenue

	30 June 2015 \$ AUD	30 June 2014 \$ AUD
<b>Revenue</b>		
<i>Operating Revenue</i>		
Sales - Medical Devices	500	18,975
Grant Received	93,488	-
<b>Total Operating Revenue</b>	<b>93,988</b>	<b>18,975</b>
<i>Non-operating Revenue</i>		
Interest	32,521	250,843
<b>Total Non-operating Revenue</b>	<b>32,521</b>	<b>250,843</b>
<b>Total Revenue</b>	<b>126,509</b>	<b>269,818</b>

## Note 4 - Segment Information

### Primary Reporting Format - Business Segments

The consolidated entity has identified its operating segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the allocation of resources.

The executive management team considers the business from both a product and a geographic perspective and has identified three reportable segments. Medical devices consist of research and development, commercialisation and sale of a suite of medical devices being developed by the Company in the subsidiaries in Israel, United States of America and Australia.

Management monitors the performance in these three regions separately. Corporate, administration and support services are provided in Australia and performance is monitored separately to the medical device business.

The Board assesses the performance of the operating segments at a number of operating levels including adjusted EBITDA. This measurement excludes the effects of certain expenditure from the operating segments such as depreciation, amortisation and finance costs.

The reportable segments are based on aggregated operating segments determined by similarity of expenses, where expenses in the reportable segments exceed 10% of the total expenses for either the current and/or previous reporting period.

30 June 2015	----- Medical Devices -----			Segment	Corporate	Total
	Australia \$ AUD	Israel \$ AUD	USA \$ AUD	Total \$ AUD	\$ AUD	\$ AUD
<b>Segment Revenue</b>						
External sales	340	93,648	-	93,988	-	93,988
Interest revenue	110	-	-	110	32,411	32,521
<b>Total Segment Revenue</b>	<b>450</b>	<b>93,648</b>	<b>-</b>	<b>94,098</b>	<b>32,411</b>	<b>126,509</b>
<b>Segment Expenses</b>						
Segment Depreciation Expenses	(3,271)	(9,851)	(18,305)	(31,427)	(1,123)	(32,550)
Segment Expenses	(1,653,660)	(749,263)	(1,299,923)	(3,702,846)	(1,855,556)	(5,558,402)
<b>Total Segment Expense</b>	<b>(1,656,931)</b>	<b>(759,114)</b>	<b>(1,318,228)</b>	<b>(3,734,273)</b>	<b>(1,856,679)</b>	<b>(5,590,952)</b>
Income Tax Expense	-	-	-	-	-	-
<b>Net Result</b>	<b>(1,656,481)</b>	<b>(665,466)</b>	<b>(1,318,228)</b>	<b>(3,640,175)</b>	<b>(1,824,268)</b>	<b>(5,464,443)</b>
<b>Assets</b>						
Segment assets	1,852,908	690,545	32,765	2,576,218	2,608,742	5,184,960
<b>Total Assets</b>	<b>1,852,908</b>	<b>690,545</b>	<b>32,765</b>	<b>2,576,218</b>	<b>2,608,742</b>	<b>5,184,960</b>
<b>Liabilities</b>						
Segment liabilities	465,866	138,780	175,997	780,643	503,920	1,284,563
<b>Total Liabilities</b>	<b>465,866</b>	<b>138,780</b>	<b>175,997</b>	<b>780,643</b>	<b>503,920</b>	<b>1,284,563</b>

# Notes to the Financial Statements *Continued.....*

30 June 2014	----- Medical Devices -----			Segment	Corporate	Total
	Australia	Israel	USA	Total		
	\$ AUD	\$ AUD	\$ AUD	\$ AUD	\$ AUD	\$ AUD
<b>Segment Revenue</b>						
External sales	14,684	4,291	-	18,975	-	18,975
Interest Revenue	-	-	545	545	250,298	250,843
<b>Total Segment Revenue</b>	<b>14,684</b>	<b>4,291</b>	<b>545</b>	<b>19,520</b>	<b>250,298</b>	<b>269,818</b>
<b>Segment Expenses</b>						
Segment Depreciation Expenses	(816)	(5,700)	(3,829)	(10,345)	(16,924)	(27,269)
Segment Expenses	(1,509,595)	(1,232,438)	(4,462,318)	(7,204,351)	(3,348,155)	(10,552,506)
<b>Total Segment Expense</b>	<b>(1,510,411)</b>	<b>(1,238,138)</b>	<b>(4,466,147)</b>	<b>(7,214,696)</b>	<b>(3,365,079)</b>	<b>(10,579,775)</b>
Income Tax Expense	-	-	-	-	-	-
<b>Net Result</b>	<b>(1,495,727)</b>	<b>(1,233,847)</b>	<b>(4,465,602)</b>	<b>(7,195,176)</b>	<b>(3,114,781)</b>	<b>(10,309,957)</b>
<b>Assets</b>						
Segment assets	1,500,007	744,440	219,096	2,463,543	8,140,666	10,604,209
<b>Total Assets</b>	<b>1,500,007</b>	<b>744,440</b>	<b>219,096</b>	<b>2,463,543</b>	<b>8,140,666</b>	<b>10,604,209</b>
<b>Liabilities</b>						
Segment liabilities	697,013	87,130	368,461	1,152,604	375,200	1,527,804
<b>Total Liabilities</b>	<b>697,013</b>	<b>87,130</b>	<b>368,461</b>	<b>1,152,604</b>	<b>375,200</b>	<b>1,527,804</b>

## Note 5 - Contingent Liabilities

### Office of the Chief Scientist- Israel

Following approval from the Office of the Chief Scientist in Israel (OCS), certain intellectual property (IP) and associated OCS grant royalty payment commitments were acquired by iSonea from Karmel Medical Acoustic Technologies Ltd (KMAT) in 2006.

The terms of the OCS grant scheme specify that once any IP developed and commercialised from these advances generates sale revenue for the company, a 3.5% of sales revenue royalty is to be paid to the OCS. The total royalty payment commitment is capped at an amount calculated by adding to the grant amounts received a London Interbank Offered Rate (LIBOR) based interest indexation factor.

As at 30 June 2015, the maximum royalty payment commitment to the OCS of all six grants which may result in commercialised IP was USD\$1,157,028 (2014: USD\$1,116,795).

### Binational Industrial Research and Development Foundation – Israel

In December 2008 the company signed a three party joint venture grant agreement with the Binational Industrial Research and Development Foundation (BIRD) and an American company Sandhill Scientific Inc. (JV partner).

Under this grant agreement iSonea received four grants totalling USD\$459,933 to assist with the joint funding of IP development in conjunction with our JV partner. The terms of these grants include a condition that if any IP developed under this agreement is commercialised, iSonea would pay a royalty amount of 5% on any revenues generated. The royalty payment commitment is capped at a maximum total value equal to the BIRD grants received by the company plus a CPI indexation factor.

On the basis of the current status of our research and development outcomes, the Company does not anticipate that any future revenues will be received from the IP developed under this co-funded grants scheme.

As at 30 June 2015, the maximum royalty payment commitment of iSonea under the BIRD JV agreement was USD\$459,933 (2014: USD\$367,622).

# Notes to the Financial Statements *Continued.....*

## Note 6 - Issued Capital

	30 June 2015		30 June 2014	
	No.	\$ AUD	No.	\$ AUD
<b>Fully Paid Ordinary Shares</b>				
Balance at beginning of year	275,913,955	95,149,981	219,675,323	77,310,846
Shares issued during the year	-	-	39,954,437	14,036,089
Shares to be issued <sup>1</sup>	-	-	-	794,481
Share issued from the exercise of options <sup>1</sup>	5,674,861	-	16,284,195	3,362,287
Transactions costs relating to share issues	-	-	-	(353,722)
<b>Total Issued Capital</b>	<b>281,588,816</b>	<b>95,149,981</b>	<b>275,913,955</b>	<b>95,149,981</b>

1. As at 30 June 2014, iSonea Limited, had 5,674,861 shares to issue to Option holders who have requested to exercise their Listed ISNOB Options at an exercise price of \$0.14 per option. iSonea Limited fulfilled this obligation on 4 July 2014.

## Note 7 - Reserves

	30 June 2015		30 June 2014	
	No.	\$ AUD	No.	\$ AUD
<b>Options</b>				
Balance at beginning of year	8,725,964	861,257	25,557,724	1,706,441
Listed Options issued during the year	-	-	1,000,000	390,000
Unlisted Options issued during the year	10,000,000	121,400	1,143,060	73,759
Share issued from the exercise of options <sup>1</sup>	(5,674,861)	-	(16,284,195)	(682,500)
Expense recorded options over vesting period	-	-	-	840,942
Lapse of options due to nil exercise	(1,258,043)	(537,351)	(2,690,625)	(1,467,385)
<b>Total Reserves</b>	<b>11,793,060</b>	<b>445,306</b>	<b>8,725,964</b>	<b>861,257</b>

1. As at 30 June 2014, iSonea Limited, had 5,674,861 shares to issue to Option holders who have requested to exercise their Listed ISNOB Options at an exercise price of \$0.14 per option. iSonea Limited fulfilled this obligation on 4 July 2014.

## Note 8 - Loss per Share

	30 June 2015	30 June 2014
Basic loss per share (cents)	(1.94)	(3.91)
Diluted loss per share (cents)	(1.94)	(3.91)
a) Net loss used in the calculation of basic and diluted loss per share	(5,464,443)	(10,309,957)
b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share	281,526,626	263,761,594
c) Potential ordinary shares, including options, are excluded from the weighted average number of shares used in the calculations of basics loss per share.		

### **Note 9 - Events Subsequent to Reporting Date**

No matters or circumstances have arisen since the end of the reporting period which significantly affected or may significantly affect the operations of the economic entity, the result of those operations or the state of affairs of the economic entity in subsequent financial years.

### **Note 10 - Audit**

These accounts are currently in the process of being audited. An Annual Report for the year ended 30 June 2015 containing the Audit Report shall be provided in due course.

# Corporate Directory

---

**AUSTRALIAN COMPANY NUMBER (ACN)**  
009 234 173

iSonea Limited is a Public Company Limited  
by shares and is domiciled in Australia.

## **DIRECTORS**

Mr Leon L'Huillier  
Dr Timothy Oldham  
Mr John Ribot-de-Bresac  
Mr David Ashmore  
Mr Ross Blair-Holt

Executive Chairman  
Non-Executive Director  
Non-Executive Director  
Non-Executive Director  
Non-Executive Director (appointed 28 Nov 2015)

## **COMPANY SECRETARIES**

Mr. Phillip Hains  
Mr. Peter Vaughan

## **PRINCIPAL PLACE OF BUSINESS**

The Rialto, Level 29,  
525 Collins Street  
Melbourne, Victoria  
AUSTRALIA 3000  
Telephone: + 61 (0)3 9824 5254  
Fax: + 61 (0)3 9822 7735

## **REGISTERED OFFICE**

The Rialto, Level 29,  
525 Collins Street  
Melbourne, Victoria  
AUSTRALIA 3000  
Telephone: + 61 (0)3 9824 5254  
Fax: + 61 (0)3 9822 7735

## **SHARE REGISTRY**

Security Transfer Registrars Pty Ltd  
770 Canning Highway  
Applecross, Western Australia, 6153  
Australia  
Telephone: +61 (0)8 9315 2333

## **SOLICITORS**

Francis Abourizk Lightowlers  
Level 14, 14 Williams Street  
Melbourne, Victoria, 3000  
Australia

## **AUDITORS**

BDO East Coast Partnership  
Level 14, 140 William Street  
Melbourne, Victoria, 3000  
Australia

## **BANKERS**

National Australia Bank (NAB)  
330 Collins Street,  
Melbourne, Victoria, 3000  
Australia

## **WEBSITES**

[www.isonea.com](http://www.isonea.com)  
[www.airsona.com.au](http://www.airsona.com.au)

## **SECURITIES QUOTED**

Australian Securities Exchange  
- Ordinary Fully Paid Shares (Code: ISN)